Literature DB >> 22411785

Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study.

Etienne Gayat1, Matthieu Resche-Rigon, Jean-Yves Mary, Raphaël Porcher.   

Abstract

Propensity score methods are increasingly used in medical literature to estimate treatment effect using data from observational studies. Despite many papers on propensity score analysis, few have focused on the analysis of survival data. Even within the framework of the popular proportional hazard model, the choice among marginal, stratified or adjusted models remains unclear. A Monte Carlo simulation study was used to compare the performance of several survival models to estimate both marginal and conditional treatment effects. The impact of accounting or not for pairing when analysing propensity-score-matched survival data was assessed. In addition, the influence of unmeasured confounders was investigated. After matching on the propensity score, both marginal and conditional treatment effects could be reliably estimated. Ignoring the paired structure of the data led to an increased test size due to an overestimated variance of the treatment effect. Among the various survival models considered, stratified models systematically showed poorer performance. Omitting a covariate in the propensity score model led to a biased estimation of treatment effect, but replacement of the unmeasured confounder by a correlated one allowed a marked decrease in this bias. Our study showed that propensity scores applied to survival data can lead to unbiased estimation of both marginal and conditional treatment effect, when marginal and adjusted Cox models are used. In all cases, it is necessary to account for pairing when analysing propensity-score-matched data, using a robust estimator of the variance.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Keywords:  bias; propensity score; simulation; survival; treatment effect

Mesh:

Year:  2012        PMID: 22411785     DOI: 10.1002/pst.537

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  45 in total

1.  LocalControl: An R Package for Comparative Safety and Effectiveness Research.

Authors:  Nicolas R Lauve; Stuart J Nelson; S Stanley Young; Robert L Obenchain; Christophe G Lambert
Journal:  J Stat Softw       Date:  2020-11-29       Impact factor: 6.440

2.  Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data.

Authors:  Rafael Santana-Davila; Kiran Devisetty; Aniko Szabo; Rodney Sparapani; Carlos Arce-Lara; Elizabeth M Gore; Amy Moran; Christina D Williams; Michael J Kelley; Jeffrey Whittle
Journal:  J Clin Oncol       Date:  2014-11-24       Impact factor: 44.544

3.  Greater risk of hip fracture in hemodialysis than in peritoneal dialysis.

Authors:  Y-J Chen; P-T Kung; Y-H Wang; C-C Huang; S-C Hsu; W-C Tsai; H-C Hsu
Journal:  Osteoporos Int       Date:  2014-02-21       Impact factor: 4.507

4.  Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors.

Authors:  Vishal Bali; Satabdi Chatterjee; Michael L Johnson; Hua Chen; Ryan M Carnahan; Rajender R Aparasu
Journal:  J Comp Eff Res       Date:  2016-07-18       Impact factor: 1.744

5.  Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics.

Authors:  C E Leonard; W B Bilker; C M Brensinger; X Han; J H Flory; D A Flockhart; J J Gagne; S Cardillo; S Hennessy
Journal:  Clin Pharmacol Ther       Date:  2016-01-17       Impact factor: 6.875

6.  Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.

Authors:  Rafael Santana-Davila; Aniko Szabo; Carlos Arce-Lara; Christina D Williams; Michael J Kelley; Jeff Whittle
Journal:  J Thorac Oncol       Date:  2014-05       Impact factor: 15.609

7.  Platinum-based concurrent chemotherapy remains the optimal regimen for nasopharyngeal carcinoma: a large institutional-based cohort study from an endemic area.

Authors:  Yahui Yu; Hu Liang; Xing Lv; Liangru Ke; Wenze Qiu; Xinjun Huang; Guoying Liu; Wangzhong Li; Xiang Guo; Yanqun Xiang; Weixiong Xia
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-14       Impact factor: 4.553

8.  Susceptible period for cardiovascular complications in patients recovering from sepsis.

Authors:  Chih-Cheng Lai; Meng-Tse Gabriel Lee; Wan-Chien Lee; Christin Chih-Ting Chao; Tzu-Chun Hsu; Si-Huei Lee; Chien-Chang Lee
Journal:  CMAJ       Date:  2018-09-10       Impact factor: 8.262

9.  Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker.

Authors:  Nicholas Y Tan; Yihong Deng; Xiaoxi Yao; Lindsey R Sangaralingham; Nilay D Shah; Andrew D Rule; John C Burnett; Shannon M Dunlay; S Jeson Sangaralingham
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2021-02-15

10.  The Impact of Antifungal Prophylaxis in Lung Transplant Recipients.

Authors:  Kelly M Pennington; Hayley J Dykhoff; Xiaoxi Yao; Lindsey R Sangaralingham; Nilay D Shah; Steve G Peters; Jason N Barreto; Raymund R Razonable; Cassie C Kennedy
Journal:  Ann Am Thorac Soc       Date:  2021-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.